Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI-Guided Ultrasound Stimulated Microbubbles + Radiation for Head and Neck Cancer
NCT04431648Phase 1Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- May 2020
- Primary completion
- May 2024
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perflutren lipid microspheres in head and neck squamous cell carcinoma (HNSCC), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Incidence of toxicity and adverse events at 90 days. Started May 2020; status: recruiting.
02
Drugs
perflutren lipid microspheres
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04431648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431648.